louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06315998: Diagnosis of Structural Heart Disease Using MCG
Official title: Accurate Identification of Structural Heart Disease Using Magnetocardiography as an Innovative and Non-invasive Tool
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Structural Heart Abnormality
Lead sponsor: Qilu Hospital of Shandong University
Sponsor class: OTHER
First posted: 2024-03-18
Enrollment: 2914
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with suspected structural heart disease who are scheduled to undergo echocardiography or cardiac magnetic resonance

Brief summary: The purpose of this prospective cohort study is to determine the parameters of cardiac magnetic imaging to identify structural heart disease using use transthoracic echocardiography or cardiac magnetic resonance as reference standard.


Eligibility criteria: Inclusion Criteria:

* Those with suspected structural heart disease who are scheduled to undergo echocardiography or cardiac magnetic resonance. Structural heart disease includes cardiomyopathy (hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, etc.), congenital heart disease (including ventricular septal defect, atrial septal defect, patent ductus arteriosus, Tetralogy of Fallot) syndrome, tricuspid valve malformation, etc.), valvular heart disease (aortic valve stenosis, mitral valve stenosis, etc.), ventricular remodeling caused by myocardial ischemia or cardiac structural changes.
* Signed the consent form.

Exclusion Criteria:

* Those with atrial fibrillation, supraventricular tachycardia, atrioventricular block and other arrhythmias that have not returned to normal;
* Those who are thought to be incapable of completing the relevant examinations by an attending physicians (or physicians with higher qualifications) due to unstable clinical conditions, metal implants, etc., or those who are unable to perform the examinations;
* Those with obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply;
* Those with malignant tumors;
* Pregnant or lactating women.

Primary outcomes:
measure: The efficacy of the MCG in identifying structural heart disease
timeFrame: from the date of enrollment until the date of discharge, up to 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: China, Shandong Qilu Hospital of Shandong University
state: Shandong
Study officials:
affiliation: Qliu Hospital of Shandong University
name: Yuguo Chen, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02686398: Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis
Official title: Immunogenicity of a Trivalent Influenza Vaccine in Patients With Chronic Kidney Disease Undergoing Hemodialysis: MF59-adjuvanted Versus Non-adjuvanted Vaccines
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Influenza
End Stage Renal Failure
Chronic Kidney Disease
Keywords: Influenza Vaccines
MF59 oil emulsion
End Stage Renal Failure on Dialysis
Lead sponsor: Korea University Guro Hospital
Sponsor class: OTHER
First posted: 2016-02-19
Enrollment: 174
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: During the 2013-2014 influenza season, CKD patients undergoing HD participated in the study. The patients were randomized into two groups (MF59-adjuvanted vaccine group or non-adjuvanted vaccine group) and were immunized with the respective vaccine. Sera were collected prior to vaccination and at 1and 6 months post vaccination. Levels of hemagglutination inhibition (HI) antibodies were measured.


Eligibility criteria: Inclusion Criteria:

* Chronic kidney disease patients undergoing hemodialysis
* Who have given written informed consent at the time of enrollment

Exclusion Criteria:

* Recipients of influenza vaccine of 2013-2014 season before the study
* History of egg allergy

Primary outcomes:
measure: Seroprotection rate (A/H1N1, A/H3N2, B)
timeFrame: 1 month after vaccination
measure: Seroconversion rate (A/H1N1, A/H3N2, B)
timeFrame: Change of titer from pre-vaccination to 1 month after vaccination
measure: GMT fold change (A/H1N1, A/H3N2, B)
timeFrame: Change of GMT from pre-vaccination to 1 month after vaccination
Secondary outcomes:
measure: Seroprotection rate (A/H1N1, A/H3N2, B)
timeFrame: 6 months after vaccination
measure: Seroconversion rate (A/H1N1, A/H3N2, B)
timeFrame: Change of titer from pre-vaccination to 6 months after vaccination
measure: GMT fold change (A/H1N1, A/H3N2, B)
timeFrame: Change of GMT from pre-vaccination to 6 months after vaccination
Other outcomes:
Locations:
Study officials:
affiliation: Korea University Guro Hospital
name: Hee Jin Cheong, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05463198: Evaluation of Physiological Variables and Detection of Blood Loss Using the Zynex Fluid Monitoring System, Model CM-1600
Official title: Evaluation of Physiological Variables and Detection of Blood Loss Using the Zynex Fluid Monitoring System, Model CM-1600
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fluid Loss
Lead sponsor: Zynex Monitoring Solutions
Sponsor class: INDUSTRY
First posted: 2022-07-18
Enrollment: 351
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The study is a prospective, non-randomized, non-blinded, non-significant risk, multi-center study enrolling up to 500 healthy adult subjects consented to undergo a whole blood donation procedure. The study will involve enrolling subjects that will undergo blood donation wearing the study device (CM-1600 Device) and capture study-required physiological parameters pre-, during, and post-donation.


Eligibility criteria: Inclusion Criteria:

* Ability to provide written consent
* Ability and willingness to comply with the study procedures and duration requirements
* 18 years of age or older
* Consented and eligible to undergo a single unit whole blood donation

Exclusion Criteria:

* Females who are pregnant or breastfeeding
* Undergone an amputation of any upper extremity
* Diagnosed with dextrocardia
* Subjects who have a pacemaker
* Subjects with body hair density which prevents adequate application of device electrodes

Primary outcomes:
measure: Change in the Relative Index (RI) After Minor Blood Loss (e.g., 500mL)
timeFrame: Recovery period following donation (10 minutes)
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: Vitalant Research Institute
state: Colorado
city: Bradenton
country: United States
facility: SunCoast Blood Centers
state: Florida
city: Columbus
country: United States
facility: ClinCept, LLC
state: Georgia
city: Chattanooga
country: United States
facility: Blood Assurance
state: Tennessee
Study officials:
References:
Clinical trial NCT05993598: The Effect of Hippotherapy Applied on Different Seating Surfaces in Children With Special Needs
Official title: The Effect of Hippotherapy Applied on Different Sitting Surfaces on Sitting Balance and Walking Speed in Children With Special Needs
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Special Needs Children
Keywords: hippotherapy
sitting balance
child with special needs
walking speed
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2023-08-15
Enrollment: 30
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The effect of hippotherapy, which will be applied to children with special needs in a single session, on sitting balance and walking speed under the supervision of a physiotherapist was investigated. 30 randomly selected children with special needs between the ages of 3-18 who were referred to the Gebze Equestrian Training Center were included in the study. The children were randomly divided into 3 groups: 10 in the saddle, 10 naked (direct contact with the horse), and 10 in the hippotherapy group, in which a cloth of different texture was placed on the horse. Each group did a 30-minute hippotherapy session in the manege area. Before the application, the sitting balance of the children was evaluated by playing the Nintendo Wii Balance Platform and the Basic Balance Game. In addition, 10 m walking test was applied for walking speed. These assessments were repeated after the 30-minute session. It was checked whether the application had an effect on balance and walking speed. Comparisons between the groups were made and it was examined which application was more effective on balance and walking speed.


Eligibility criteria: Inclusion Criteria:

* Having a child with special needs between the ages of 3-18,
* Children with a diagnosis of Cerebral Palsy (CP) have a level of 1 and 2 according to the Gross Motor Function Classification System,
* Ability to understand simple commands,
* Ability to sit unaided for at least 10 seconds,

Exclusion Criteria:

* Presence of clinical conditions that may pose an obstacle
* Lack of cooperation
* Presence in another study performed at the same time as the study
* Lack of family approval.

Primary outcomes:
measure: BeCure Balance Evaluation System
timeFrame: 11 weeks
Secondary outcomes:
measure: Ten(10) Meter Walking Test(sec)
timeFrame: 11 weeks
measure: Gross Motor Function Classification System (GMFCS)
timeFrame: 11 weeks
Other outcomes:
Locations:
city: Kocaeli
country: Turkey
facility: Gebze Municipality Equestrian Training Center
state: Gebze
Study officials:
affiliation: Department of Physiotherapy & Rehabilitation
name: Ebru SEVER, Lecturer
role: STUDY_DIRECTOR
References:
Clinical trial NCT05521945: Effect of Intermittent Fasting Among Adult Population
Official title: Effect of Intermittent Fasting on Body Composition, Clinical Health Markers and Memory Status Among Adult Population: A Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intermittent Fasting
Keywords: Intermittent fasting
Memory status
physical activity
customized diet plan
24- hour dietary recall
Multifactorial Memory Questionnaire
Lead sponsor: University of the Punjab
Sponsor class: OTHER
First posted: 2022-08-30
Enrollment: 90
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Our study aims to assess the effects of intermittent fasting among the healthy population.

Detailed description: Research needs to be conducted to find the effects of intermittent fasting on humans as it might not have the same favorable effects on the memory of a human brain compared to mice. This study will also help to assess the consequences of different intermittent fasting regimens on different individuals (based on age, sex, body mass index , memory status and physical activity etc)

Eligibility criteria: Inclusion Criteria:

* BMI greater or equal to 25kg/m2.

Exclusion Criteria:

not given consent having secondary or syndromic forms of obesity taking medication for weight gain or reduction undergoing bariatric surgery

* diabetic pregnant women breastfeeding mothers chronic disease

Primary outcomes:
measure: Weight(in kg)
timeFrame: three months
measure: Height (in cm)
timeFrame: three months
measure: Waist (in cm)
timeFrame: three months
measure: Hip measurement(in cm)
timeFrame: three months
Secondary outcomes:
measure: Clinical Health Markers
timeFrame: three months
measure: blood sugar
timeFrame: three months
measure: blood pressure
timeFrame: three months
Other outcomes:
measure: Memory Status
timeFrame: three months
Locations:
city: Lahore
country: Pakistan
facility: University of the Punjab
state: Punjab
Study officials:
affiliation: University of the Punjab
name: Javeria Saleem, Ph.D
role: STUDY_DIRECTOR
References:
Clinical trial NCT00957645: Central Post-Stroke Pain - a Prospective Study
Official title: Central Post-Stroke Pain - a Prospective Study of Consecutively Admitted Patients With Recent Stroke
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain
Keywords: Central post-stroke pain
post-stroke pain
shoulder pain
Lead sponsor: Danish Pain Research Center
Sponsor class: OTHER
First posted: 2009-08-12
Enrollment: 275
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive stroke patients admitted to the Stroke Unit of the Department of Neurology at Aarhus University Hospital between February 2008 to October 2009

Brief summary: Part 1: The purpose of the first part of the study is to investigate the prevalence of pain at stroke onset and 3 and 6 months after stroke in a consecutive cohort of stroke patients admitted to a stroke unit.

Part 2: The purpose of the second part of the study is to identify patients who develop central post-stroke pain within the first 6 months following stroke and to try to identify early prognostic factors for the development of pain.

Detailed description: Part 1:

* Within 3 days of admission: medical history, pain history, sensory examination
* Telephone follow-up at 3 and 6 months post-stroke: pain history

Part 2:

* Medical history, Pain history, Sensory examination

Eligibility criteria: Inclusion Criteria:

* Recent cerebrovascular stroke

Exclusion Criteria:

* Severe dementia, aphasia or psychosis
* Patients who cannot cooperate at time of inclusion
* Patients who do not understand Danish

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Danish Pain Research Center
name: Henriette Klit, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03850145: Educational Program Through Video Conference for Inhaled Therapies in Cystic Fibrosis Patients
Official title: Evaluation of the Efficacy of an Educational Program Through Video Conference
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cystic Fibrosis
Keywords: inhaled therapy
physiotherapist
educational program
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2019-02-21
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: CF patients consulting at the CF center of Montpellier (France)

Brief summary: Educational programs are essential for cystic fibrosis patients who need to take several different drugs every day. Compliance is often klow in these patients, and clinicals and paramedics try to increase it, through educational programs. As for inhaled therapies, the CF center of Montpellier uses a video conference tool to educate patients. The program may involve either the physiotherapist or the doctor or both. Through the present study, the investigators would like to evaluate the current practice at the CF center of Montpellier and verify if patients feel that the physiotherapist could handle the program on his own, without the support of a physician.


Eligibility criteria: Inclusion criteria:

* CF patients
* patient regularly assessed at the CF center of Montpellier
* major patients
* patients who recently enrolled a video conference educational program or who will soon be part of it

Exclusion criteria:

* patients not able to participate to a video conference educational program, due to lack of tools at their home

Primary outcomes:
measure: acceptability of the therapeutic education program by videoconference
timeFrame: 1 day
measure: need for the presence of the referring physician in relation to a session of therapeutic education carried out by the physiotherapist alone
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Davide CAIMMI
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03176745: Number of Multiple Breath Washout Tests in Adults With Pulmonary Disease and Healthy Controls
Official title: Determination of the Optimal Number of Multiple Breath Washout Tests in Adults With Pulmonary Disease and Healthy Controls
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Controls
Chronic Obstructive Pulmonary Disease
Bronchial Asthma
Sarcoidosis
Lead sponsor: Universitätsmedizin Mannheim
Sponsor class: OTHER
First posted: 2017-06-05
Enrollment: 153
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: inpatients, outpatients, students, employees

Brief summary: The investigators aim to determine the optimal number of measurements required for multiple-breath-washout derived lung function parameters in adults with pulmonary disease as well as in healthy controls


Eligibility criteria: Inclusion criteria:

- informed consent

Exclusion Criteria:

* inability to perform multiple breath washout testing

Primary outcomes:
measure: change of lung clearance index (LCI) as determined by multiple breath washout
timeFrame: 60 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Trinkmann F, Gotzmann J, Saur D, Schroeter M, Roth K, Stach K, Borggrefe M, Saur J, Akin I, Michels JD. Multiple breath washout testing in adults with pulmonary disease and healthy controls - can fewer measurements eventually be more? BMC Pulm Med. 2017 Dec 11;17(1):185. doi: 10.1186/s12890-017-0543-y.
Clinical trial NCT03059745: Use of Robotics for Cholecystectomy; Retrospective Review of Outcomes, Set Up and Learning Curves
Official title: Evolution of Robotic Cholecystectomy; the U.C. Davis Experience.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cholecystitis
Cholelithiasis
Keywords: Cholecystitis
Cholelithiasis
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2017-02-23
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients which have undergone a robotic assisted laparoscopic cholecystectomy

Brief summary: Comparing the use of surgical robotics during a Cholecystectomy, comparing different platforms and approaches (multi port verses single port).

Detailed description: This study is a restrospective review of charts, including operating room notes as well as operating room documentation of procedures. Currently there are numerous methods considered to be the Standard of Care in the surgical treatment of Cholecystitis, or Cholelithiasis, including Open Surgery, Laparoscopic, and Robotic Assisted Laparoscopic Surgery. This study retrospectively reviews the intraoperative and post operative clinical outcomes of Laparoscopic and Robotic Assisted Surgery at U.C. Davis Medical Center to: 1) establish the role of robotics in laparoscopic surgery, and 2) to assess the learning curve by surgeons.

Eligibility criteria: Inclusion Criteria:

* Patients that have undergone robotic assisted laparoscopic cholecystectomy

Exclusion Criteria:

* Patients under the age of 18, or not choosing to have surgery.

Primary outcomes:
measure: Comparing hernia rates between multi-port verses single port approaches.
timeFrame: June 2004 through May 2015
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis Health System
state: California
city: Sacramento
country: United States
facility: Univesity of California Davis Health System
state: California
Study officials:
affiliation: University of California, Davis
name: Tamas Vidovszky, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05581745: A2 to O Lung Transplants
Official title: Blood Group A2 Donor to Blood Group O Recipient Lung Transplantation
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Lung Transplant
ABO Incompatibility
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2022-10-14
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O recipients in an effort to increase the available donor pool. The aim of this study is to determine both the feasibility and safety of this specific type of ABO-incompatible lung transplant, and the impact of this practice on reducing transplant wait times among blood group O lung transplant candidates. This would represent the first prospective study of ABO-incompatible lung transplants worldwide.


Eligibility criteria: Inclusion Criteria:

* first lung transplant
* blood group O recipient
* low pre-operative anti-A antibody titers
* consent to study participation

Exclusion Criteria:

* re-transplant
* multiorgan transplant
* positive virtual crossmatch at time of transplant

Primary outcomes:
measure: Post-transplant anti-A antibody titers
timeFrame: post-op day 5 or day 12
measure: Primary graft dysfunction grade
timeFrame: post-op day 0, 1, 2, 3
measure: Incidence of hyperacute antibody-mediated rejection
timeFrame: post-op day 1, 2
measure: C4d positivity on transbronchial biopsy samples
timeFrame: 1 year
measure: Incidence and severity of acute cellular rejection
timeFrame: 1 year
measure: Bleeding
timeFrame: post-op day 1-7
measure: Infection
timeFrame: 10 years
measure: Graft function
timeFrame: 10 years
measure: Incidence of malignancy
timeFrame: 10 years
measure: Chronic lung allograft dysfunction
timeFrame: 10 years
measure: Time to death or re-transplantation
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Toronto General Hospital, University Health Network
state: Ontario
Study officials:
affiliation: University Health Network, Toronto
name: Shaf Keshavjee, MD MSc FRCSC FACS
role: PRINCIPAL_INVESTIGATOR
References: